RespireRx Pharmaceuticals — 28th Annual ROTH Conference 2016
35 slides from RespireRx Pharmaceuticals's conference presentation, Mar 11, 2016
Slide 1: RespireRx Pharmaceuticals - 28th Annual ROTH Conference
RespireRx Pharmaceuticals Inc OTC QB: RSPI James S. Manuso, Ph.D., President & CEO 28™ ANNUAL ROTH CONFERENCE MARCH 15, 2016, LA‘ |A NIGUEL, CA Medicines for Respiratory Diseases
Slide 2: Forward Looking Statements
Forward Looking Statements GQ) RespireRx Pharmaceuticals Inc The matters discussed in this presentation that are not historical facts are "forward-looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," "anticipates," "intends," “e
Slide 3: Breath
Breath GQ) RespireRx "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life.” beeees Abbot George Burke
Slide 4: Innovative Medicines for Respiratory Diseases
Innovative Medicines for Respiratory Diseases Resp pireRx Pharmaceuticals Inc o Two proprietary, small molecule platforms o Three Phase 2 or Phase 2-ready development programs o Three pre-clinical programs o Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent
Slide 5: Company Focus
° ° ° ° ° Company Focus WN Sleep Apneas = Dronabinol for Obstructive Sleep Apnea (OSA) = Ampakines for Central Sleep Apnea (CSA) Drug-induced Respiratory Depression (RD) - Ampakines = Acute use — surgical anesthesia/sedation = Semi-acute use — post-surgical pain management with opioids = Chronic use
Slide 6: Respiratory Diseases Product Pipeline
Respiratory Diseases Product Pipeline (A)Resp pireRx Pharmaceuticals Inc Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea Central Sleep Apnea —— ap CX1739 Opioid-induced RD Spinal Damage/Pompe Combination Formulation CX717 with Opioids for Reduced Repertory Depressi
Slide 7: Sleep Apnea
Sleep Apnea A) RespireRx o Sleep Apnea = Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep = Three types: Obstructive, Central & Mixed o The Sleep Apnea Market is Large = 18 million U.S. adults suffer from moderate or severe sleep apneas =
Slide 8: Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA) A) RespireRx Pharmaceuticals Inc o Obstructive Sleep Apnea (OSA): a decrease or complete halt in airflow during sleep = Induced by relaxation of muscles during sleep = Soft tissue in back of throat collapses and obstructs upper airway o Significant morbidity due to stro
Slide 9: CPAP Efficacy is Severely Limited
CPAP Efficacy is Severely Li Patient Compliance Standard of Care Works as an air splint to keep upper airway open during sleep 30% of diagnosed patients never initiate CPAP treatment when prescribed a machine Over 50% of patients stop using CPAP in the first year Many CPAP users wear the device for
Slide 10: Dronabinol: Breakthrough Treatment for OSA
Dronabinol: Breakthrough Treatment for OSA Resp pireRx Pharmaceuticals Inc o Mechanism of Action = Dronabinol is (delta 9) THC, a cannabinoid agonist o Background = Schedule Ill drug available by prescription, with a low risk of addiction = Approved for the treatment of anorexia in AIDS patients and
Slide 11: Completed Phase 2A Trial of Dronabinol in OSA
Completed Phase 2A Trial of Dronabinol in OSA Ad RespireRx Pharmaceuticals Inc o Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA o Placebo (N=5) or dronabinol (N=17) for 21 days « 2.5, 5 and 10 mg/night studied with weekly dose escalation o Overnight polyso
Slide 12: Dronabinol Proven to Reduce Apnea in OSA Subjects
ronabinol Proven to Reduce Apnea in OSA Subjects Reduction in Sleep Apnea 40% P=0.17 Dronabinol Placebo P<0.01 RespireRx Pharmaceuticals Inc 12
Slide 13: Apnea Suppression as a Function of Dose and Time
Apnea Suppression as a Function of Dose and Time RespireRx Pharmaceuticals Inc 1st Half 2nd Half AAHI versus Baseline 86 R&B Bw we n=17 n= 13, n=8 The plasma half-life of dronabinol is 2 — 4 hours. 13
Slide 14: Ongoing Dronabinol Phase 2B Clinical Trial in OSA
Ongoing Dronabinol Phase 2B Clinical Trial in OSA (A) Resp ireRx o Sponsored and led by U of Illinois o 4 major centers, fully funded by NIH o Potentially pivotal for an NDA submission o Doses: Placebo, 2.5 mg, 10 mg qd o 120 subjects (40/group, 6 weeks dosing) o Data expected Q3/2016 o Meet with FD
Slide 15: Protecting Dronabinol in the Market
Protecting Dronabinol in the Market A) RespireRx o Licensed issued Method-of-Use patent for dronabinol in OSA = Expires in 2025 o Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label o Off-label use of generics and medical marijuana a
Slide 16: The Dronabinol Opportunity
The Dronabinol Opportunity A) RespireRx Pharmaceuticals Inc Impact on Pa Commercial Opportunity First medicine available for OSA Changes the nature of OSA treatment Ease of Use/Better Patient Compliance Broadly expands prescriber base from sleep specialists to include primary care physicians and car
Slide 17: Central Sleep Apnea
Central Sleep Apnea Resp pireRx Pharmaceuticals Inc o Caused by a lack of drive from the brain to breathe during sleep o Manifestations of CSA = 70% of chronic narcotic users = Up to 40% of heart failure patients = 5% of sleep apnea patients are idiopathic o No medicine or device is approved for the
Slide 18: Severity of CSA is Correlated with Increased Mortality
Severity of CSA is Correlated with Increased Mortality in P Heart Failure Patients RespireRx 0) 9) 2 ‘6 AHI less than 5 per hour ul ‘ooo AHI equal or greater than 5 per hour ra) Reducing Central : | Sleep Apnea May @ Reduce Mortality in a Heart Failure Patients eal 4 0D DO 1H M 1 O MH MH WH W W HO B
Slide 19: AMPAKINES - A Novel Class of Medicines
AMPAKINES -— A Novel Class of Medicines A) Resp pireRx Pharmaceuticals Inc AMPA Receptors Mediate Synaptic Transmission in the Brain AMPAKINE o Glutamate is the major excitatory neurotransmitter in the CNS o Fast excitatory transmission is mediated by AMPA-type glutamate receptors o Ampakines are po
Slide 20: AMPAKINES - Novel Treatments for Respiratory Depression
AMPAKINES — Novel Treatments for Respiratory Depression (A) RespireRx Pharmaceuticals Inc ‘<) esophagus PreBétzinger PreBétzinger Complex Complex o Neurons in this brainstem region control inspiratory breathing rhythm o PreBotC neurons use AMPA receptors for signaling o Opioids and other depressants
Slide 21: CX1739: A Third Generation, Oral Ampakine
CX1739: A Third Generation, Oral Ampakine in Phase 2 RespireRx Pharmaceuticals Inc o Targeted Indications = Central Sleep Apnea (CSA) = Reversal and prevention of opioid-induced Respiratory Depression = Combination formulation with an opioid for treatment of chronic pain o Stage of Development = Suc
Slide 22: CX1739: Completed Phase 2A in Sleep Apnea
CX1739: Completed Phase 2A in Sleep Apnea WN RespireRx seceded foc Inc Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a single dose of 90
Slide 23: Patient Selection: CX1739 Was More Effective in Mixed and Central Sleep Apneas
Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas GQ Resp pireRx Pharmaceuticals Inc Obstructive Apneas Mixed Apneas Central Apnea 3 6 12 30 5 10 piers ic Rc SE oe4 SE 8 £ G 20. £G £3 ot w £3 we 6 2 3% 2¢ 23 Si 6. 2 au 4. ze 0 au Ea ; : CJ ; 0 0 0 = rs) yo Yo SS
Slide 24: Drug-induced Respiratory Depression
° ° ° Drug-induced Respiratory Depression Resp pireRx Pharmaceuticals Inc RD is the most frequent lethal side effect of opioid use Acute and Semi-Acute Use of opioids « ~25M patients/year at risk for Respiratory Depression (hospitalized, peri- and post-surgical opioid patients) Chronic Opioid Use «
Slide 25: Ampakines Prevent Opioid-induced Respiratory Depression
Ampakines Prevent Opioid-induced Respiratory Depression Resp pireRx Pharmaceuticals Inc o Two clinical studies in normal, healthy volunteers with CX717, a second-generation Ampakine o Moderate Respiratory Depression was induced experimentally by infusion of the opioid, Alfentanil o Respiratory and a
Slide 26: CX717 Prevents Opioid-induced Respiratory Depression in Humans
CX717 Prevents Opioid-induced Respiratory Depression in Humans GQ Resp pireRx Pharmaceuticals Inc 16 NS —_—_ (Placebo —™. waecx717 ge 12 £ a *P<0.01 = 8 NS - Not Significant oO 2 a 4 Data are expressed as the basal respiratory rate. N= 15 and 16 per group. CX717 dose is 1500mg. 0. Baseline +Alfentan
Slide 27: CX717 Does Not Interfere With the Analgesic Properties of Opioids
CX717 Does Not Interfere With the Analgesic Properties of Opioids BW RespireRx che ot ied Inc Analgesia 2.0 [Placebo 215 waacx717 2 2 o 5 1.0 NS. 2) c cc a 0.5: Delivery of a electrical stimulation to finger ’ ’ 0.0: Alfentanil reduced the pain sensitivity Baseline +Alfentanil +Naloxone (produced an
Slide 28: CX1739: Phase 2A in Opioid-Induced Respiratory Depression
CX1739: Phase 2A in Opioid-Induced Respiratory Depression GQ Rese pireRx Pharmaceuticals Inc Protocol Antagonism of Opioid-Induced Respiratory Depression by CX1739 with Preservation of Opioid Analgesia Design Randomized, Blinded, Placebo-controlled, Cross-Over with Dose Escalation Dosing Each subjec
Slide 29: Key Objectives (Pending Financing)
Key Objectives for 20 (Pending Financing) GQ Resp pireRx Pharmaceuticals Inc Compound Indication Status Estimated Estimated Start Date Completion Dronabinol Obstructive Sleep Apnea Phase 2B Underway 3Q2016 CX1739 Opioid-induced RD Phase 2A 1Q2016 2Q2016 Central Sleep Apnea Phase 2A 3Q2016 2Q2017 CX1
Slide 30: Respiratory Diseases Product Pipeline
Respiratory Diseases Product Pipeline (A)Resp pireRx Pharmaceuticals Inc Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea Central Sleep Apnea —— ap CX1739 Opioid-induced RD Spinal Damage/Pompe Combination Formulation CX717 with Opioids for Reduced Repertory Depressi
Slide 31: NIH-Supported Programs in Drug Abuse
NIH-Supported Programs in Drug Abuse A) RespireRx o Non-Core Programs in Drug Abuse and Addiction = Cocaine and Amphetamines = Research and development program with NIDA = NIDA contracts with specialist labs and pays for animal studies = Company provides compounds and retains all rights 31
Slide 32: Capital Structure & Market Metrics
Capital Structure (t & Market Metrics usands of shares) Total as of September 30, 2015 Common Stock 477,221 Common Stock Equivalents of all Convertibles (Preferred Stock and Convertible Notes) 95,934 Common Stock Equivalents of all Options and 380,247 Warrants Total 953,402 March 8, 2016 Closing pri
Slide 33: Management and Directors
Management and Directors A James Manuso Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell Katie MacFarlane James Sapirstein John Greer President, CEO & Vice Chairman CSO & Chairman VP, Secretary/Treasurer, Director CFO, Director Senior VP, R& D Director CCO Agile Therapeutics Director CEO
Slide 34: Innovative Medicines for Respiratory Diseases
Innovative Medicines for Respiratory Diseases Resp pireRx Pharmaceuticals Inc o Two proprietary, small molecule platforms o Three Phase 2 or Phase 2-ready development programs o Three pre-clinical programs o Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent
Slide 35: RespireRx Pharmaceuticals - 28th Annual ROTH Conference
RespireRx Pharmaceuticals Inc OTC QB: RSPI James S. Manuso, Ph.D., President & CEO 28™ ANNUAL ROTH CONFERENCE MARCH 15, 2016, LA‘ |A NIGUEL, CA Medicines for Respiratory Diseases 35
RespireRx Pharmaceuticals — 28th Annual ROTH Conference 2016 on 6ix